{
  "source": "PA-Notification-Sprycel.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1096-13\nProgram Prior Authorization/Notification\nMedication Sprycel® (dasatinib)\nP&T Approval Date 8/2008, 6/2009, 6/2010, 9/2010, 12/2010, 9/2011, 8/2012, 8/2013,\n2/2014, 2/2015, 2/2016, 11/2017, 11/2018, 10/2019, 10/2020, 10/2021,\n10/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nSprycel (dasatinib) is a tyrosine kinase inhibitor indicated for newly diagnosed adults with\nPhiladelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.\nSprycel is also indicated for treatment of adults with chronic, accelerated, or myeloid or lymphoid\nblast phase Ph+ CML with resistance or intolerance to prior therapy including Gleevec®\n(imatinib), for the treatment of adults with Ph+ acute lymphoblastic leukemia (ALL) with\nresistance or intolerance to prior therapy, for the treatment of pediatric patients 1 year of age and\nolder with Ph+ CML in chronic phase, and for the treatment of pediatric patients 1 year of age\nand older with Ph+ ALL in combination with chemotherapy. The National Comprehensive\nCancer Network (NCCN) also recommends the use of Sprycel in the following: BCR-ABL1\npositive CML, in gastrointestinal stromal tumor in patients with PDGFRA exon 18 mutations,\nmetastatic chondrosarcoma, in recurrent chordoma, in myeloid/lymphoid neoplasms with\neosinophilia and ABL1 rearrangement, and in cutaneous melanoma with metastatic or\nunresectable tumors with activating mutations of KIT as second-line or subsequent therapy for\ndisease progression, intolerance, and/or projected risk of progression with BRAF-targeted\ntherapy.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of othe",
    "atically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Sprycel will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n1\nB. Philadelphia Chromosome-Positive or BCR-ABL1-Positive Chronic Myeloid\nLeukemia\n1. Initial Authorization\na. Sprycel will be approved based on the following criterion:\n(1) Diagnosis of Philadelphia chromosome-positive or BCR-ABL1-Positive chronic\nmyeloid leukemia\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sprycel will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sprycel therapy\nAuthorization will be issued for 12 months.\nC. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)\n1. Initial Authorization\na. Sprycel will be approved based on the following criterion:\n(1) Diagnosis of Philadelphia chromosome-positive acute lymphoblastic leukemia\n(Ph+ALL)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sprycel will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sprycel therapy\nAuthorization will be issued for 12 months.\nD. Gastrointestinal Stromal Tumor (GIST)\n1. Initial Authorization\na. Sprycel will be approved based on the following criterion:\n(1) Diagnosis of gastrointestinal stromal tumor (GIST) with PDGFRA exon 18\nmutations\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\n2. Reauthorization\na. Sprycel will be approved based on the following criterion:\n(1) Patient does not s",
    "8\nmutations\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\n2. Reauthorization\na. Sprycel will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sprycel therapy\nAuthorization will be issued for 12 months.\nE. Chondrosarcoma\n1. Initial Authorization\na. Sprycel will be approved based on the following criterion:\n(1) Diagnosis of metastatic chondrosarcoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sprycel will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sprycel therapy\nAuthorization will be issued for 12 months.\nF. Chordoma\n1. Initial Authorization\na. Sprycel will be approved based on the following criterion:\n(1) Diagnosis of recurrent chordoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sprycel will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sprycel therapy\nAuthorization will be issued for 12 months.\nG. Myeloid/Lymphoid Neoplasms with Eosinophilia\n1. Initial Authorization\na. Sprycel will be approved based on both of the following:\n© 2024 UnitedHealthcare Services, Inc.\n3\n(1) Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with\neosinophilia\n-AND-\n(2) Patient has an ABL1 rearrangement\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sprycel will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sprycel therapy.\nAuthorization will be issued for 12 months.\nH. Cutaneous Melanoma\n1. Initial Authorization\na. Sprycel will be approved based on all of the following:\n(1) Diagnosis of cutaneous melanoma\n-AND-\n(2) Tumors are metastatic or unresectable\n-AND-\n(3) Contains activating mutations of KIT\n-AND-\n(4) Used as second-line or subsequent therapy for disease progression, intolerance,\nand/or projected risk of prog",
    "rs are metastatic or unresectable\n-AND-\n(3) Contains activating mutations of KIT\n-AND-\n(4) Used as second-line or subsequent therapy for disease progression, intolerance,\nand/or projected risk of progression with BRAF-targeted therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sprycel will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sprycel therapy.\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n4\nI. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits Step Therapy, and/or Medical Necessity may be in place.\n4. References:\n1. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; July 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed\nSeptember 10, 2024.\nProgram Prior Authorization/Notification - Sprycel (dasatinib)\nChange Control\n2/2014 Updated references.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n2/2015 Annual review. Updated GIST to include PDGFRA D842V mutation.\nUpdated background and references.\n2/2016 Annual revie",
    "inistrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n2/2015 Annual review. Updated GIST to include PDGFRA D842V mutation.\nUpdated background and references.\n2/2016 Annual review. Updated background and CML coverage criteria to\ninclude BCR-ABL1 positive diagnosis. Updated references.\n11/2017 Annual review. Updated background and criteria removing acute\nlymphoblastic lymphoma as no longer recommended by NCCN.\n11/2018 Updated background and criteria to include NCCN recommended use in\nchordoma and chondrosarcoma.\n10/2019 Annual review. Added general NCCN recommended review criteria.\nUpdated background and references.\n10/2020 Annual review. Updated background and coverage criteria to include\nNCCN recommended use in myeloid/lymphoid neoplasms with\n© 2024 UnitedHealthcare Services, Inc.\n5\neosinophilia. Updated references.\n10/2021 Annual review with no change to clinical coverage criteria. Updated\nreference.\n10/2022 Annual review with no changes to clinical coverage criteria. Updated\nreferences. Added state mandate footnote.\n10/2023 Annual review. Added criteria for cutaneous melanoma per NCCN\nGuidelines. Updated background and references.\n10/2024 Annual review. Updated coverage criteria to include NCCN language\nfor use in gastrointestinal stromal tumors. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n6"
  ]
}